Oric Pharmaceuticals, Inc. Income Statement
ORIC / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| SG&A Expense | $33.2M | $28.8M | $25.6M | $25.1M | $22.0M | $13.4M | $5.7M | $3.3M |
| R&D Expense | $109.8M | $114.1M | $85.2M | $61.7M | $56.9M | $35.9M | $22.8M | $19.0M |
| Operating Income | -$143.0M | -$142.9M | -$110.8M | -$91.8M | -$78.9M | -$74.2M | -$28.6M | -$22.4M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$129.5M | -$127.8M | -$100.7M | -$89.1M | -$78.7M | -$73.7M | -$26.9M | -$21.4M |
| EPS (Basic) | -$1.47 | -$1.83 | -$1.96 | -$2.25 | -$2.07 | - | - | - |
| EPS (Diluted) | -$1.47 | -$1.83 | -$1.96 | -$2.25 | -$2.07 | - | - | - |
| Shares Outstanding | 87.8M | 69.7M | 51.5M | 39.7M | 38.0M | 21.9M | 1.9M | 1.7M |